Regeneron Pharmaceuticals, Inc. (REGN)

Check out top investors' recommendation for REGN
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
537.20
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage consist of EYLEA for the treatment of ophthalmologic diseases; and ZALTRAP for oncology. The company’s earlier stage clinical programs include various human monoclonal antibodies, such as REGN88 for rheumatoid arthritis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis and allergic asthma; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; REGN846 for atopic dermatitis; and REGN1500, REGN1033, and REGN1154. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Sector:
Industry:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Edward Tenthoff Piper Jaffray Buy   Jul 21, '17     557.00  Jul 21, '18  N/A 
Dane Leone Macquarie Research Equities Buy   Jun 30, '17     540.00  Jun 30, '18  N/A 
Geoff Porges High Peaks Buy   Jun 22, '17       Jun 22, '18  N/A 
Christopher Raymond Robert W. Baird & Co., Inc. Buy   Jun 22, '17     547.00  Jun 22, '18  N/A 
Edward Tenthoff Piper Jaffray Buy   Jun 20, '17     557.00  Jun 20, '18  N/A 
Alethia Young Deutsche Bank Securities Buy   May 23, '17     485.00  May 23, '18  N/A 
Joseph Schwartz Leerink Swann Llc Buy   Mar 20, '17       Mar 20, '18  N/A 
Joseph Schwartz Leerink Swann Llc Buy   Jan 10, '17       Jan 10, '18  N/A 
Adnan Butt RBC Capital Markets Buy   Jan 06, '17     598.00  Jan 06, '18  N/A 
Christopher Raymond Robert W. Baird & Co., Inc. Buy   Dec 12, '16       Dec 12, '17  N/A 
Adnan Butt RBC Capital Markets Buy   Dec 05, '16     626.00  Dec 05, '17  N/A 
Joseph Schwartz Leerink Swann Llc Buy   Dec 01, '16     500.00  Dec 01, '17  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Oct 28, '16     520.00  Oct 28, '17  N/A 
Joseph Schwartz Leerink Swann Llc Buy   Oct 25, '16     513.00  Oct 25, '17  N/A 
Adnan Butt RBC Capital Markets Buy   Oct 04, '16     648.00  Oct 04, '17  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Sep 23, '16     520.00  Sep 23, '17  N/A 
Joseph Schwartz Leerink Swann Llc Buy   Sep 21, '16     530.00  Sep 21, '17  N/A 
Joseph Schwartz Leerink Swann Llc Buy   Aug 06, '16     511.00  Aug 06, '17  N/A 
Ying Huang Barclays Buy   May 11, '16   371.86  522.00  May 11, '17  16.06% 
Joseph Schwartz Leerink Swann Llc Buy   Apr 04, '16   405.30  523.00  Apr 04, '17  -5.46% 
< previous12345